CEVEC to launch CAP-T expression system

CEVEC Pharmaceuticals, a German firm specializing in the development of  complex therapeutic proteins using human cell-based expression systems,  is to launch its CAP-T transient expression system for fast, serum-free  and high-yield protein production.

Fast process times, high yields and authentic human post-translational  modifications, especially with complex and highly-glycosylated proteins,  are key features and the firm says this makes it an ideal tool for  screening, assay development, target validation, drug discovery,  early-stage pre-clinical drug development, and lead optimization.

Chief executive Rainer Lichtenberger said: "starting with transient  protein expression using CAP-T and moving forward with stable expression  using CAP cells, CEVEC is now able to offer a continuum for rapid and  versatile biopharmaceutical drug development from initial research ideas  up to GMP-compliant manufacturing of clinical samples and market  supplies."